

Resignation of Non-Executive Director

Brisbane, Australia, 30th March 2020 – ResApp Health Limited (ASX:RAP) today advises that Mr Nathan Buzza has resigned from his role as a Non-Executive Director on the company's board of directors, effective 31 March 2020.

"The board of ResApp sincerely thanks Mr Buzza for his valued contribution to the company," said ResApp Chairman, Roger Aston. "Nathan has provided valuable input and insights to the company since he joined the board in 2017, and we wish him the best in his future endeavours."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, pneumonia, bronchiolitis, croup, asthma/reactive airway disease exacerbation, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp's smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit www.resapphealth.com.au.

Contacts for ResApp Health

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.